These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Discovery of novel 1,3,5-triazine derivatives as an antidiabetic agent in Wistar rats via inhibition of DPP-4.
    Author: Gupta A, Bhat HR, Singh UP.
    Journal: Future Med Chem; 2023 May; 15(10):829-852. PubMed ID: 37307171.
    Abstract:
    Aim: To develop imeglimin-inspired novel 1,3,5-triazine derivatives as antidiabetic agents. Materials & methods: These derivatives were synthesized and tested against DPP enzymes. Compound 8c was tested for in vivo antidiabetic activity in streptozotocin-induced diabetes in Wistar rats by estimating various biochemical parameters. Docking experiments were also performed. Results: Compound 8c was identified as a selective and potent DPP-4 inhibitor. It was proficiently docked into the catalytic triad of Ser 630, Asp 710 and His740 in S1 and S2 pockets of DPP-4. In experimental animals, it also showed dose-dependent improvement in blood glucose, blood insulin, bodyweight, lipid profile and kidney and liver antioxidant profiles. Conclusion: This study demonstrated the discovery of imeglimin-inspired novel 1,3,5-triazines as a potent antidiabetic agent. Type 2 diabetes mellitus is a complicated heterogeneous and polygenic metabolic disease. Therefore, in search of a potent antidiabetic drug, the authors have synthesized 13 novel 1,3,5-triazine-morpholino-pyrazole derivatives, compounds 8(a–m), and they were subsequently tested for in vitro inhibitory activity against a panel of DPP enzymes (DPP-4, DPP-8 and DPP-9) where they are found active toward DPP-4 while inactive toward DPP-8 and DPP-9. Compound 8c was observed to be the most potent DPP-4 inhibitor and showed excellent interaction with DPP-4 in docking analysis. Furthermore, in high-fat, low-dose streptozotocin-induced diabetes in rats, compound 8c significantly reduced blood glucose, cholesterol, triglyceride, low-density lipoprotein, very low-density lipoprotein and reactive species levels and increased high-density lipoprotein levels, possibly by the potent inhibition of DPP-4. It also showed intense antioxidant activity. The potent DPP-4 inhibition, antidiabetic and antioxidant activity render compound 8c a probable lead for antidiabetic drug discovery.
    [Abstract] [Full Text] [Related] [New Search]